GI CANCERS

Findings from the CheckMate 9DW trial support the FDA approval of nivolumab and ipilimumab in unresectable hepatocellular carcinoma

Jennifer Chan, MD, MPH, discussed outcomes of treating neuroendocrine tumors (NETs) with cabozantinib depending on whether they were pancreatic NETs or extrapancreatic NETs.

The primary end point of overall response rate has been met in the COMPANION-002 trial of tovecimig and paclitaxel in advanced biliary tract cancer.

The GI Cancers Symposium revealed new therapies for specific cancer subsets and progress in chimeric antigen receptor T-cell therapies for solid tumors.

Neoadjuvant immunotherapy shows antitumor activity in mismatch repair deficient/MSI gastric/gastroesophageal junction adenocarcinoma.

Yelena Y. Janjigian, MD, discusses the long-term survival data from the KEYNOTE-811 trial of pembrolizumab plus trastuzumab and chemotherapy for the treatment of patients with HER2-positive locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

Jennifer Chan, MD, MPH, discussed the recent FDA approval of cabozantinib in pancreatic and extrapancreatic neuroendocrine tumors.

Yelena Y. Janjigian, MD, discusses the standard approval of pembrolizumab plus trastuzumab and chemotherapy for the treatment of patients with HER2-positive gastric or gastroesophageal junction adenocarcinoma.

Jennifer Chan, MD, MPH, discussed the findings from the phase 3 CABINET trial leading to the FDA approval of cabozantinib in patients with neuroendocrine tumors.

PEP-010 was granted FDA orphan drug designation for the treatment of pancreatic cancer.

Harry H. Yoon, MD, MHS, discusses tislelizumab and platinum-containing chemotherapy in unresectable or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1 at a level of 1 or higher.

The combination of pembrolizumab, trastuzumab, and chemotherapy is now approved in HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma.

The FDA granted orphan drug designation to HLX22 for gastric cancer, advancing global phase 3 trials to improve first-line treatment.

A phase 3 trial plans to evaluate Pro-ocular for the treatment of patients with ocular graft-vs-host disease.

Ken Kato, MD, discussed the FDA approval of tislelizumab for the first-line treatment of esophageal squamous cell carcinoma.

Ken Kato, MD, PhD, and Harry H. Yoon, MD, MHS, discussed the recent FDA approval of tislelizumab in the first line for patients with esophageal squamous cell carcinoma.

The TEDOPaM trial evaluating a novel maintenance therapy approach for advanced/metastatic pancreatic ductal adenocarcinoma has met its primary end point.

Marwan G. Fakih, MD, discusses the next steps for the clinical development of the balstilimab plus botensilimab in microsatellite stable metastatic colorectal cancer without liver metastases.

MATTERHORN is the first global phase 3 trial to show improved event-free survival with an immunotherapy combo vs standard care in this patient population.

Trastuzumab deruxtecan demonstrated a significant survival benefit in HER2-positive metastatic gastric cancer in the phase 3 DESTINY-Gastric04 trial.

Tislelizumab plus chemotherapy is now FDA-approved for metastatic esophageal squamous cell carcinoma with a tumor PD-L1 expression of 1 or higher.

David Zhen, MD, discussed the relevance of nivolumab in the upper gastrointestinal cancer population.

The FDA granted RMAT designation to nogapendekin alfa and CAR-NK for reversing lymphopenia in patients with cancer, with promising survival data in metastatic pancreatic cancer and non–small cell lung cancer.

T-DM1 was tolerable in HER2-positive biliary tract adenocarcinoma but did not significantly improve progression-free survival.

David B. Zhen, MD, discusses the results of the phase 3 CheckMate 649 trial in patients with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.